Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2004

01-08-2004

Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer

Authors: Eardie A. Curry III, Daryl J. Murry, Christy Yoder, Karen Fife, Victoria Armstrong, Harikrishna Nakshatri, Michael O’Connell, Christopher J. Sweeney

Published in: Investigational New Drugs | Issue 3/2004

Login to get access
Metadata
Title
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer
Authors
Eardie A. Curry III
Daryl J. Murry
Christy Yoder
Karen Fife
Victoria Armstrong
Harikrishna Nakshatri
Michael O’Connell
Christopher J. Sweeney
Publication date
01-08-2004
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2004
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/B:DRUG.0000026256.38560.be

Other articles of this Issue 3/2004

Investigational New Drugs 3/2004 Go to the issue

OriginalPaper

A novel mammalian cell-based approach for the discovery of anticancer drugs with reduced cytotoxicity on non-dividing cells

OriginalPaper

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

OriginalPaper

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

OriginalPaper

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

OriginalPaper

Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer

OriginalPaper

Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits